Background: Patients with heartburn as their main complaint but normal oesophageal mucosa at endoscopy are classified as having endoscopy-negative gastro-oesophageal reflux disease (GORD). They have mainly postprandial reflux and low total acid exposure and could possibly be managed with a non-systemic drug. In such patients we examined the effect of a pectin-based raft-forming anti-reflux agent (Aflurax (Idoflux)) on the severity of heartburn.
Methods: Patients with heartburn but with normal/erythematous oesophageal mucosa (n = 65) were randomized to double-blind treatment with two 1200-mg tablets of Aflurax or two placebo tablets four times daily for 4 weeks. The main outcome measure was heartburn severity on day 15 and day 29.
Results: The number of patients scoring heartburn severity on day 15 as none, mild, moderate, and severe were 6, 14, 8, and 3, respectively, with Aflurax versus 2, 6, 13, and 11 with placebo (P < 0.05). No further treatment effect was found on day 29.
Conclusion: Aflurax reduces heartburn in patients with endoscopy-negative GORD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365529708996533 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alternative vs. conventional treatment given on-demand for gastroesophageal reflux disease: a randomised controlled trial.
BMC Complement Altern Med
February 2009
Department of Medicine, Innlandet Hospital Trust, Gjøvik, Norway.
Background: Alternative treatments are commonly used for various disorders and often taken on-demand. On-demand treatment of gastroesophageal reflux disease (GERD) with pharmaceutical products is an established, cost-effective strategy. Comparisons between alternative medicine and pharmaceutical products are rare.
View Article and Find Full Text PDFThe efficacy of a pectin-based raft-forming anti-reflux agent in endoscopy-negative reflux disease.
Scand J Gastroenterol
August 1997
Dept. of Medical Gastroenterology S, Odense University Hospital, Denmark.
Background: Patients with heartburn as their main complaint but normal oesophageal mucosa at endoscopy are classified as having endoscopy-negative gastro-oesophageal reflux disease (GORD). They have mainly postprandial reflux and low total acid exposure and could possibly be managed with a non-systemic drug. In such patients we examined the effect of a pectin-based raft-forming anti-reflux agent (Aflurax (Idoflux)) on the severity of heartburn.
View Article and Find Full Text PDFEfficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease.
Eur J Gastroenterol Hepatol
May 1997
Department of Medical Gastroenterology, Odense University Hospital, Denmark.
Objective: Gastro-oesophageal reflux disease may be treated with a drug forming a floating neutral raft in the stomach. The pectin-based raft-forming anti-reflux agent Aflurax (Idoflux) was examined, first regarding reduction of oesophageal acid exposure, and next as to its efficacy as maintenance treatment in patients with healed oesophagitis.
Design: Double-blind, placebo-controlled randomized clinical trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!